California startup Pinoyr is using $62 million of VC-backed funding to target antibodies in the tumor in environment. :
California startup Pionyr is using $62 million of VC-backed funding to target antibodies in the tumor microenvironment. The early-stage, San Francisco-based biotech has a batch of preclinical antibody programs, two of which are nearing IND-enabling studies targeting solid tumors. These programs are directed at myeloid tuning in the tumor microenvironment. The new cash boost sees the company's overall money raised swell to $72 million since 2015.